These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29175897)

  • 21. Levodopa in the treatment of Parkinson's disease: a consensus meeting.
    Agid Y; Ahlskog E; Albanese A; Calne D; Chase T; De Yebenes J; Factor S; Fahn S; Gershanik O; Goetz C; Koller W; Kurth M; Lang A; Lees A; Lewitt P; Marsden D; Melamed E; Michel PP; Mizuno Y; Obeso J; Oertel W; Olanow W; Poewe W; Pollak P; Tolosa E
    Mov Disord; 1999 Nov; 14(6):911-3. PubMed ID: 10584663
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Daily defined doses of parkinsonian drugs in Alcoi].
    Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
    Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
    Moegle C; Grillon A; Anheim M; Lipsker D; Velter C
    Rev Neurol (Paris); 2020 May; 176(4):292-293. PubMed ID: 32139181
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
    Metman LV; van den Munckhof P; Klaassen AA; Blanchet P; Mouradian MM; Chase TN
    Neurology; 1997 Sep; 49(3):711-3. PubMed ID: 9305328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract]   [Full Text] [Related]  

  • 30. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
    Altmann V; Schumacher-Schuh AF; Rieck M; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2016 Apr; 17(5):481-8. PubMed ID: 27019953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reply to letter: Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
    Marano M; Salomone G; di Biase L; Di Lazzaro V; Melgari JM
    Parkinsonism Relat Disord; 2016 Apr; 25():114-5. PubMed ID: 26698016
    [No Abstract]   [Full Text] [Related]  

  • 36. [A differentiated approach to Parkinson's disease treatment in early stage of the disease].
    Selikhova MV; Piatnitskiĭ AN; Aristova RA; Belikova LP; Vialkova AB; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):24-9. PubMed ID: 15270296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.
    Voon V; Fernagut PO; Wickens J; Baunez C; Rodriguez M; Pavon N; Juncos JL; Obeso JA; Bezard E
    Lancet Neurol; 2009 Dec; 8(12):1140-9. PubMed ID: 19909912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
    Olanow CW; Nakano K; Nausieda P; Tetrud JA; Manyam B; Last B; Block G; Liss C; Bush D
    Clin Neuropharmacol; 1991 Jun; 14(3):235-40. PubMed ID: 2070363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa: back to the future.
    Zappia M; Colosimo C; Poewe W
    J Neurol; 2010 Nov; 257(Suppl 2):S247-8. PubMed ID: 21080184
    [No Abstract]   [Full Text] [Related]  

  • 40. Levodopa: the story so far.
    Abbott A
    Nature; 2010 Aug; 466(7310):S6-7. PubMed ID: 20739934
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.